A Phase II Trial of Tremelimumab (CP-675,206) in Patients With Advanced Refractory or Relapsed Melanoma

Journal of Clinical Oncology - United States
doi 10.1200/jco.2008.26.15_suppl.9023
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Phase I/Ii Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas

American Journal of Hematology
Hematology
2017English

Phase I/Ii Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

Oncologist
Cancer ResearchMedicineOncology
2015English

A Phase II Study of Docetaxel in Patients With Relapsed and Refractory Ewing's Tumours

Sarcoma
Nuclear MedicineRadiologyImagingOncology
2003English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Cancer
Cancer ResearchOncology
2010English

Phase II Trial of Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer, With Assessment of Methylguanine-Dna Methyltransferase as a Potential Biomarker

Clinical Cancer Research
Cancer ResearchOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy